stockrowTELA Bio, Inc.
TELA Healthcare Medical Devices
TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024.
- Revenue
- −4.49%
- EPS
- +9.09%
- Free cash flow
- −17.7%
- Total debt
- +35.5%
Quarter to June 2026, against a year earlier
Follow TELA
Alert me
TELA Bio, Inc. (TELA) EV/Sales
As of 5 November 2026, TELA Bio, Inc. (TELA) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from −0.9× (March 2020) to 15.3× (June 2020); the current reading is higher than 21% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | (26.81%) |
| FY2024 | 1.1× | (56.56%) |
| FY2023 | 2.5× | (44.36%) |
| FY2022 | 4.5× | (24.11%) |
| FY2021 | 5.9× | (29.29%) |
| FY2020 | 8.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 1.9× | 0.00% |
| FY2017 | 1.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | 32.12% |
| Mar 2026 | 0.7× | (13.77%) |
| Dec 2025 | 0.8× | (26.34%) |
| Sep 2025 | 1.1× | (14.28%) |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NSYS Nortech Systems Incorporated compare | 0.2× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| CVRX CVRx, Inc. compare | 0.7× |
| RPID Rapid Micro Biosystems, Inc. compare | 0.8× |
| TELA TELA Bio, Inc. | 1.0× |
| QTI QT Imaging Holdings, Inc. compare | 1.3× |
| NSPR InspireMD, Inc. compare | 2.5× |
| MDAI Spectral AI, Inc. compare | 2.7× |
| ELUT Elutia Inc. compare | 3.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)